Rise in gold prices led to robust gold jewellery & coin sales
Smaller towns driving demand
Recovery 77% in Jun to 98% in Sep quarter
50% Tanishq stores concentrated in rural areas
Wedding season ,diwali to further boost jewellery demand #titan#Nifty#sensex#StockMarket
Reopening of stores, malls, vaccine may increase footfalls in Q3,Q4
Launched 'Gift a Titan' & new jewellery division ' Rooted from Zoya'
Launched its 1st smartwatch 'Titan connected X'
Taneira launched 1st Chennai store ,total 13 stores functional
Net sales down 2.6% ,PAT down 37% ,Ebidta margin down 480bps ,jewellery sales up 8.8% to 38.4bn on 38% higher gold prices
Watches sales down 44.3%
Expects to add 34 stores in Fy21,14 added so far @TitanCompanyLtd#market#dalalstreet
• • •
Missing some Tweet in this thread? You can try to
force a refresh
#glandpharma
Injectable focused B2B company
Mkt includes US,Europe,India,Australia
Niche area - sterile injectables,Oncology,Opthalmic solns
Focus -complex injectables,first to file,NCE-1, 505(b)(2) filings
Chinese promoter Shanghai Fosun Pharma is a global pharma major #pharma
Fosun acquired controlling stake in gland 74% in 2017 for $1.09 bn
Gland has 267 ANDA filings in the US Mkt, 215 approved
267 filings - 191 sterile injectables, 50 oncology ,26 ophthalmic
Out of 267,101 ANDA are owned by Gland of which 71 approved
Good regulatory compliance
No #USFDA warning letter till date
7 mftng facilities - 4 finished Formulations, 3 API
API facilities 100% captive consumption
63% of Fy20 revenue of 2633 cr were from US mkt
Focus on injs with high entry barrier, limited competition, strict regulatory reqs
@IndianEnergyXch
Transformation drivers 1) Decarbonization - use of solar & wind ,RE (renewable energy) 2) Decentralisation - RE a threat to centralized energy productn 3) Digitization 4) Democratization- peer 2 peer energy trading
Changing energy mix 2020/ 2022 /2030 % of contribution
Thermal 62 /53 /35
Wind 10 /12 /17
Solar 9 / 20/ 36
Hydro 12 / 10 /8
Electricity value chain 4 parts
Generation - Transmission - Distribution - Consumption
Power sector construct
Long term 90%
Short term 10%
Power markets in developed countries are in range 30 - 80% of total power demand ,India 5%
Share of exchange in total generation
2016 - 2.9 %
2021 - 5.2%
Share of ST market in total generation
2016 - 9.9%
2021 - 10.3%
Exchange mkt & ST MKT as % of total gen
2016 29.9
2021 50.2
#Dixon key beneficiary of GOI PLI scheme
Through its subsidiary Padget electronics, Dixon made 2 applications for phones costing < 15000 ,70% India mobile mkt share
Incentive of 4 to 6% under PLI subject to a cap
Total investment 200crs ,50 cr/yr till 2025 #dixontechnologies
Post expansion revenue share of mobiles to jump to 44 from 12% currently
Ramp up capacity from 3 mn today to 15-16 mn over next few yrs ,aim for revenue 28-30000 crs over next 5 yrs
In talks 3 large players
Set top boxes, delivered 5.2 lakh to jio,dish,Citi
Order book 0.3mn/mon
Dixon is both OEM Player & ODM ( original design manufacturer)
Expanding capacities in Android & Linux TV ,semi automatic and top load washing machines
Current capacity 4 mn TV sets ,30%LED Mkt,acquired new customers Samsung,Nokia,Ramos capacity to 5.5 mn #Nifty#stocks
@JubilantLifeSci
Q2fy21 Revenue up 4.8% yoy to 2347.9 crs led by traction in CMO/Generics in Pharma & Life sciences in LSI segment
- Radiopharma business impacted by Covid & launch of macroaggregated Albumin (MAA) by competitor Curium(jubilant was sole player) #pharma#Nifty
MAA business witnessed price & mkt share erosion
-DTPA business impacted by decrease in ventilation scan due to covid
-Generic business growth led by traction existing products,launch of Remdesivir
-JLS to launch Remdesivir in 70 countries, exported API to US & injs in India
Radiopharma 90% & allergy business 100% precovid levels
-Partnership with SOFIE Biosciences in molecular theranostics
- JLS to double DDDS capacity by Fy22
- LSI business speciality declined 2% & nutritional grew 11% led by VIT D exports to EU while ethyl acetate muted growth
@GranulesIndia
Q2fy21
Revenue up 22.7% to 858 crs
Formulations up 22.4% yoy 430 crs
API up 17% to 255
PFI up 32.6% to 173 crs
Vizag unit V commissioned for API ,oncology segment,
Company plans gradual shift from commoditized API to more complex drugs/ Formulations #stocks
Company expects to commission MUPS block by Q3fy22
- Revenue contribution of core mols dropped to 70 from 80-85% end of Fy20
- #granules has 32 ANDA approved ,expect to launch 6 of these in Fy21
- Revised PAT guidance to 30% post Fy21 from 25% earlier #StockMarket#Nifty
Company plans 7-9 product filings/year, atleast 5 for the US market
- Top 5 mols contributed 70%
- Capex guidance of 3.5 to 4 bn for fy21 & 3bn for Fy22
- Relaunch Metformin 750 mg in US over next year
- EU sales 23 % expected to reach 28% by Fy23, US sales to decline to 43%
Q2 went well for Room AC industry,uptick retail demand, pent up demand
Overall electronic & consumer durables witnessed a good quarter
Inventory levels back to normal
Anticipate better H2fy21 #stock#StocksToWatch#Nifty#sensex
GOI banned import of refrigerant fill ACs, approx 30% of fully built RACs were imported mkt size 4000 crs , atmanirbhar bharat initiative,oppurtunity for domestic RAC players
Not easy for OEMs to import non-refrigerant fill ACs,unpack,gas fill test,negates cost advantage
#amberenterprises completed QIP 400 cr in Q2fy21, money used for debt repayment,capex,WC ,acquire additional 20% stake in Sidwal,company ready to grab mkt share in RAC
China plus 1 unfolding,global MNC enquiring about RAC & components
Amber started export of components to US